VTGN - Vistagen secures new U.S. patent for PH80 nasal spray for migraine

• The USPTO has granted a patent for Vistagen's ( NASDAQ: VTGN ) PH80 nasal spray for treatment of migraine.
• VTGN shares up 6.8% premarket.
• The newly issued patent will be in effect until at least 2040.
• PH80 is an investigational pherine nasal spray designed with a potential rapid-onset mechanism of action for the treatments for migraine.
• Vistagen’s recently completed acquisition of Pherin Pharmaceuticals resulted in the full ownership of intellectual property rights worldwide to five pherine drug candidates, including, the newly issued PH80 patent for the treatment of migraine, among others .

For further details see: